Dr. Chahine raises the concern that the guideline committee did not include any pharmacists. The guideline committee was established by the American Thoracic Society and Infectious Diseases Society of America years ago and was vetted internally by both of those organizations. This preceded the current emphasis of both societies on establishing diverse, multidisciplinary committees. Nevertheless, the guideline was reviewed by several pharmacists through the Society of Infectious Diseases Pharmacists, and numerous questions and comments were raised, which we responded to in a point-by-point fashion, and a revised guideline was reviewed and endorsed by the Society of Infectious Diseases Pharmacists. So, pharmacists participated in and made important contributions to the guideline development process.
Dr. Schuetz raises the concern that we did not explore all situations in which procalcitonin measurement might be useful in managing patients with suspected CAP. As we noted at the start of the document, to limit the scope and provide a guideline of reasonable length, we explicitly chose to focus on the management of patients with radiographically confirmed CAP. The management of patients with suspected CAP but no radiographic evidence of pneumonia is outside the scope of the guideline. We would add that most trials that evaluate therapeutic treatments and other management decisions similarly focus on this more defined population. Finally, we did acknowledge that serial measurement of procalcitonin might have a role in limiting the duration of antibiotic treatment, but because the current guideline recommends shorter treatment for all patients who achieve early clinical stability (e.g., 5 d total), the benefits of serial procalcitonin measurement are significantly reduced.
Fabre and colleagues raise several important issues related to the role of antimicrobial stewardship in interpreting the guideline recommendations. First, as noted in the guideline, when multiple antibiotic options are provided, the final choice must represent a balance of risks and benefits for the individual patient. We specifically identified emerging concerns related to fluoroquinolone use and provided a link to the U.S. Food and Drug Administration website that provides up-to-date safety information. Thus, we agree that these concerns should impact individual treatment decisions, especially for patients at increased risk of these adverse events. Second, we acknowledge that several trials have examined the safety of b-lactam monotherapy for inpatients with CAP. The study by Postma and colleagues (2) was discussed by the guideline committee, and the study is cited in the full online version of the guideline and summarized in the online supplement. In that pragmatic trial, we noted that nearly 25% of enrolled patients did not have radiographic confirmation of CAP, and in the b-lactam monotherapy arm, 39% of patients received additional antibiotic coverage for atypical organisms. Furthermore, it is important to recognize that b-lactam monotherapy may not be sufficient in all inpatient populations, especially patients with more severe CAP, and severity of illness varies across trials and hospitals. With the advent of more home-based treatment programs, the severity of illness of hospitalized patients with CAP is rising, and this influenced our decision not to endorse b-lactam monotherapy for inpatients. Of note, in contrast to the prior guideline, we did endorse b-lactam monotherapy for outpatients without comorbidities. Finally, although we agree that influenza (and other viruses) can be the sole causative agent in patients with CAP, we could not identify any highlevel evidence supporting the decision to withhold initial empiric antibacterial therapy in any patients with radiographically confirmed CAP, even when influenza infection is confirmed. Moreover, although the overall frequency of bacterial complications in all patients with influenza is low, the frequency is much higher among patients with radiographically confirmed pneumonia (3). In the absence of an accurate tool to distinguish between patients with viral infection alone and those with viral infection plus bacterial superinfection, we supported initial empiric antibacterial therapy for all patients with CAP. We agree that future studies should explore the role of tests and predictive algorithms to safely guide a more restrictive empiric treatment approach. n
